Article

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk

2024-01-23

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background and Aims</h4> APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that are actively pursued as pharmacological targets to treat dyslipidemia and reduce the risk of atherosclerotic cardiovascular disease. Here, we used human genetic data to compare the predicted therapeutic and adverse effects of APOC3, ANGPTL3, and ANGPTL4 inactivation. <h4>Methods</h4> We conducted drug-target Me...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dde61a27-7f71-5926-b37b-b038705e6fc9
DOI: 10.1101/2024.01.23.24301541

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskDOI 10.1101/2024.01.23.24301541Read

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases preventionSemantic proximity Read

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.Semantic proximity Read

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseasesSemantic proximity Read

Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.Semantic proximity Read

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular DiseasesSemantic proximity Read

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read

Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysisSemantic proximity Read

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read

Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.Semantic proximity Read

Evaluating genetically-predicted causal effects of lipoprotein(a) in human diseases: a phenome-wide Mendelian randomization studySemantic proximity Read